Back to California

SB-1094 • 2026

Prescription drugs.

Prescription drugs.

Crime Education Healthcare
Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor
Weber Pierson
Last action
2026-05-26
Official status
Referred to Coms. on B. & P. and HEALTH.
Effective date
Not listed

Plain English Breakdown

The official source material does not provide information on the enforcement mechanisms for these rules.

Prescription Drugs Law Changes

The bill allows pharmacists to substitute biosimilar or interchangeable biological products when filling prescriptions and requires health insurance policies to cover previously approved drugs if they are still medically necessary.

What This Bill Does

  • Allows pharmacists to choose a different biological product, called a biosimilar or interchangeable with the original, when filling prescriptions unless the doctor says not to do so.
  • Requires health insurance policies to continue covering prescription drugs that were already approved and are still medically necessary for treating patients' conditions.

Who It Names or Affects

  • Pharmacists and pharmacies
  • Health insurance companies
  • Patients who need prescription drugs

Terms To Know

Biosimilar
A drug that is very similar to an already approved biological product but may be less expensive.
Interchangeable
A term used when a biosimilar can replace the original drug without changing how well it works or causing any extra side effects.

Limits and Unknowns

  • The bill does not specify what happens if someone disagrees with being asked to try a less expensive option.
  • It is unclear how much this will affect costs for patients and insurance companies.
  • There are no details on how the state will enforce these rules.

Bill History

  1. 2026-05-26 California Legislative Information

    Referred to Coms. on B. & P. and HEALTH.

  2. 2026-05-19 California Legislative Information

    In Assembly. Read first time. Held at Desk.

  3. 2026-05-18 California Legislative Information

    Read third time. Passed. (Ayes 38. Noes 0.) Ordered to the Assembly.

  4. 2026-05-05 California Legislative Information

    Read second time. Ordered to third reading.

  5. 2026-05-04 California Legislative Information

    From committee: Be ordered to second reading pursuant to Senate Rule 28.8.

  6. 2026-04-24 California Legislative Information

    Set for hearing May 4.

  7. 2026-04-23 California Legislative Information

    From committee: Do pass and re-refer to Com. on APPR. (Ayes 10. Noes 0.) (April 22). Re-referred to Com. on APPR.

  8. 2026-04-10 California Legislative Information

    Set for hearing April 22.

  9. 2026-04-08 California Legislative Information

    Read second time and amended. Re-referred to Com. on HEALTH.

  10. 2026-04-07 California Legislative Information

    From committee: Do pass as amended and re-refer to Com. on HEALTH. (Ayes 10. Noes 0. Page 3740.) (April 6).

  11. 2026-03-26 California Legislative Information

    Set for hearing April 6.

  12. 2026-03-17 California Legislative Information

    March 23 hearing postponed by committee.

  13. 2026-03-16 California Legislative Information

    Set for hearing March 23.

  14. 2026-02-26 California Legislative Information

    Referred to Coms. on B. P. & E.D. and HEALTH.

  15. 2026-02-17 California Legislative Information

    From printer. May be acted upon on or after March 16.

  16. 2026-02-13 California Legislative Information

    Introduced. Read first time. To Com. on RLS. for assignment. To print.

Official Summary Text

SB 1094, as amended, Weber Pierson.
Prescription drugs.
(1) The Pharmacy Law governs the practice of pharmacy in this state, including the permissible duties of licensed pharmacists. A knowing violation of the Pharmacy Law is a misdemeanor. Existing law authorizes a pharmacist to select an alternative biological product when filling a prescription order for a prescribed biological product if the alternative biological product is interchangeable, as defined, and the prescriber does not personally indicate in a specified manner that a substitution is not to be made.
This bill would additionally authorize a pharmacist to select an alternative biological product when filling a prescription order for a prescribed biological product if the alternative biological product is
a biosimilar,
biosimilar to,
as defined,
or interchangeable with, the prescribed reference product,
and the prescriber does not personally indicate in a specified manner that a substitution is not to be made. Because a knowing violation of this provision would be a misdemeanor, the bill would create a new crime, thereby imposing a state-mandated local program.
(2) Existing law, the Knox-Keene Health Care Service Plan Act of 1975, provides for the licensure and regulation of health care service plans by the Department of Managed Health Care, and makes a willful violation of the act a crime. Existing law provides for the regulation of health insurers by the Department of Insurance.
Existing law prohibits a health care service plan that covers prescription drug benefits from
limiting or excluding coverage for a drug that was previously approved for coverage if an enrollee continues to be prescribed that drug and that drug is appropriately prescribed and considered safe and effective for treating the enrollee’s medical condition. Existing law specifies that these provisions do not preclude a prescribing provider from prescribing another drug covered by the plan that is medically appropriate for the enrollee or a generic drug substitution authorized by a pharmacist, as specified.
This bill would prohibit a health insurance policy that covers prescription drug benefits from limiting or excluding coverage for a drug that was previously approved for coverage if an insured continues to be prescribed that drug and the drug is appropriately prescribed, continues to be medically necessary for the treatment of the insured’s medical condition, and is considered safe and effective for treating the insured’s medical condition as demonstrated by
evidence-based practice, as specified. With respect to both health care service plans and health insurers, the bill would specify that these provisions do not prohibit a prescribing provider from prescribing a biosimilar drug substitution authorized by a pharmacist, as described above. The bill would
specify
that these provisions do not prohibit
authorize
a health care service plan, health insurer, or utilization review organization
from requiring
to require
an enrollee or insured to try an AB-rated generic
equivalent,
equivalent of a brand name drug, a
biosimilar, or interchangeable biological product
that is the same or similar to the brand name drug or
of
a
reference product that was previously approved for coverage by the plan or insurer if specified conditions are met. Because a violation of these provisions by a health care service plan would be a crime, the bill would impose a state-mandated local program.
(3) The California Constitution requires the state to reimburse local agencies and school districts for certain costs mandated by the state. Statutory provisions establish procedures for making that reimbursement.
This bill would provide that no reimbursement is required by this act for a specified reason.

Current Bill Text

Read the full stored bill text
Download Bill PDF